Individualizing treatment for Waldenstrom’s macroglobulinemia

References

• Dimopoulos MA, Panayiotidis P, Moulopoulos LA, Sfikakis P, Dalakas M. Waldenstrom’s macroglobulinemia: clinical features, complications, and management. J. Clin. Oncol.18, 214–226 (2000).
   PubMed Web of Science ®Google Scholar
• Ghobrial IM, Witzig TE. Waldenstrom macroglobulinemia. Curr. Treat. Options Oncol.5, 239–247 (2004).
   PubMedGoogle Scholar
• Dimopoulos MA, Kyle RA, Anagnostopoulos A, Treon SP. Diagnosis and management of Waldenstrom’s macroglobulinemia. J. Clin. Oncol.23, 1564–1577 (2005).
   PubMed Web of Science ®Google Scholar
• Owen RG, Treon SP, Al-Katib A et al. Clinicopathological definition of Waldenstrom’s macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom’s Macroglobulinemia. Semin. Oncol.30, 110–115 (2003).
   PubMed Web of Science ®Google Scholar
• Jemal A, Murray T, Ward E et al. Cancer statistics, 2005. CA Cancer J. Clin.55, 10–30 (2005).
   PubMed Web of Science ®Google Scholar
• Herrinton L, Weiss, NS. Incidence of Waldenstrom’s macroglobulinemia. Blood82, 3148–3150 (1993).
   PubMed Web of Science ®Google Scholar
• Ghobrial IM, Fonseca R, Gertz MA et al. Prognostic model for disease-specific and overall mortality in newly diagnosed symptomatic patients with Waldenstrom macroglobulinaemia. Br. J. Haematol.133, 158–164 (2006).
   PubMed Web of Science ®Google Scholar
• Vijay A, Gertz MA. Waldenstrom macroglobulinemia. Blood109(12), 5096–5103 (2007).
   PubMed Web of Science ®Google Scholar
• McMaster M. Familial Waldenstrom’s macroglobulinemia. Semin. Oncol.30, 146–152 (2003).
   PubMed Web of Science ®Google Scholar
• Treon SP, Hunter ZR, Aggarwal A et al. Characterization of familial Waldenstrom’s macroglobulinemia. Ann. Oncol.17, 488–494 (2006).
   PubMed Web of Science ®Google Scholar
• Kyle RA, Therneau TM, Rajkumar SV et al. Long-term follow-up of IgM monoclonal gammopathy of undetermined significance. Blood102, 3759–3764 (2003).
   PubMed Web of Science ®Google Scholar
• Schnitzler L, Schubert B, Boasson M, Gardais J, Tourmen A. Urticaire chronique, lésions osseuses, macroglobulinémie IgM, maladie de Waldenstrom? Bull. Soc. Fr. Derm. Syph.81, 363–367 (1974).
   Google Scholar
• Gertz M, Kyle RA, Noel P. Primary systemic amyloidosis: a rare complication of immunoglobulin M monoclonal gammopathies and Waldenstrom’s macroglobulinemia. J. Clin. Oncol.11, 914–920 (1993).
   PubMed Web of Science ®Google Scholar
• Ghobrial IM, Gertz MA, Fonseca R. Waldenstrom macroglobulinaemia. Lancet Oncol.4, 679–685 (2003).
   PubMed Web of Science ®Google Scholar
• Dhodapkar MV, Jacobson JL, Gertz MA et al. Prognostic factors and response to fludarabine therapy in patients with Waldenstrom macroglobulinemia: results of United States intergroup trial (Southwest Oncology Group S9003). Blood98, 41–48 (2001).
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Hamilos G, Zervas K et al. Survival and prognostic factors after initiation of treatment in Waldenstrom’s macroglobulinemia. Ann. Oncol.14, 1299–1305 (2003).
   PubMed Web of Science ®Google Scholar
• Kyle RA, Treon SP, Alexanian R et al. Prognostic markers and criteria to initiate therapy in Waldenstrom’s macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom’s Macroglobulinemia. Semin. Oncol.30, 116–120 (2003).
   PubMed Web of Science ®Google Scholar
• Dimopoulos M, Gika D, Zervas K et al. The international staging system for multiple myeloma is applicable in symptomatic Waldenstrom’s macroglobulinemia. Leuk. Lymphoma45, 1809–1813 (2004).
   PubMed Web of Science ®Google Scholar
• Morel P, Duhamel A, Gobbi P et al. International prognostic scoring system for Waldenstrom’s macroglobulinemia. Blood113(18), 4163–4170 (2009).
   PubMed Web of Science ®Google Scholar
• Leleu X, Soumerai J, Roccaro A et al. Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenstrom macroglobulinemia treated with nucleoside analogs. J. Clin. Oncol.27, 250–255 (2009).
   PubMed Web of Science ®Google Scholar
• Gertz MA, Anagnostopoulos A, Anderson K et al. Treatment recommendations in Waldenstrom’s macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom’s Macroglobulinemia. Semin. Oncol.30, 121–126 (2003).
   PubMed Web of Science ®Google Scholar
• Treon SP, Morel P, Leblond V, Fermand JP. Report of the Third International Workshop on Waldenstrom’s macroglobulinemia. Clin. Lymphoma5, 215–216 (2005).
   PubMedGoogle Scholar
• Treon SP, Emmanouilides C, Kimby E et al. Extended rituximab therapy in Waldenstrom’s macroglobulinemia. Ann. Oncol.16, 132–138 (2005).
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, O’Brien S, Kantarjian H et al. Fludarabine therapy in Waldenstrom’s macroglobulinemia. Am. J. Med.95, 49–52 (1993).
   PubMed Web of Science ®Google Scholar
• Weber DM, Dimopoulos MA, Delasalle K, Rankin K, Gavino M, Alexanian R. 2-chlorodeoxyadenosine alone and in combination for previously untreated Waldenstrom’s macroglobulinemia. Semin. Oncol.30, 243–247 (2003).
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Weber D, Delasalle KB, Keating M, Alexanian R. Treatment of Waldenstrom’s macroglobulinemia resistant to standard therapy with 2-chlorodeoxyadenosine: identification of prognostic factors. Ann. Oncol.6, 49–52 (1995).
   PubMed Web of Science ®Google Scholar
• McLaughlin P, Estey E, Glassman A et al. Myelodysplasia and acute myeloid leukemia following therapy for indolent lymphoma with fludarabine, mitoxantrone, and dexamethasone (FND) plus rituximab and interferon α. Blood105, 4573–4575 (2005).
   PubMed Web of Science ®Google Scholar
• Treon SP, Gertz MA, Dimopoulos M et al. Update on treatment recommendations from the Third International Workshop on Waldenstrom’s macroglobulinemia. Blood107, 3442–3446 (2006).
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Zervas C, Zomas A et al. Extended rituximab therapy for previously untreated patients with Waldenstrom’s macroglobulinemia. Clin. Lymphoma3, 163–166 (2002).
   PubMedGoogle Scholar
• Dimopoulos MA, Zervas C, Zomas A et al. Treatment of Waldenstrom’s macroglobulinemia with rituximab. J. Clin. Oncol.20, 2327–2333 (2002).
   PubMed Web of Science ®Google Scholar
• Gertz MA, Rue M, Blood E, Kaminer LS, Vesole DH, Greipp PR. Multicenter Phase 2 trial of rituximab for Waldenstrom macroglobulinemia (WM), an Eastern Cooperative Oncology Group Study (E3A98). Leuk. Lymphoma45, 2047–2055 (2004).
   PubMed Web of Science ®Google Scholar
• Ghobrial I, Fonseca R, Greipp PR et al. Initial immunoglobulin M ‘flare’ after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia: an Eastern Cooperative Oncology Group Study. Cancer101, 2593–2598 (2004).
   PubMed Web of Science ®Google Scholar
• Treon S, Branagan AR, Hunter Z, Santos D, Tournhilac O, Anderson KC. Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenstrom’s macroglobulinemia. Ann. Oncol.15, 1481–1483 (2004).
   PubMed Web of Science ®Google Scholar
• Treon SP, Hunter Z, Barnagan AR. CHOP plus rituximab therapy in Waldenstrom’s macroglobulinemia. Clin. Lymphoma5, 273–277 (2005).
   PubMedGoogle Scholar
• Vijay A, Gertz MA. Current treatment options for Waldenstrom macroglobulinemia. Clin. Lymphoma Myeloma8, 219–229 (2008).
   PubMedGoogle Scholar
• Treon SP, Hatjiharissi E, Leleu X et al. Novel agents in the treatment of Waldenstrom’s macroglobulinemia. Clin. Lymphoma Myeloma7(Suppl. 5), S199–S206 (2007).
   Google Scholar
• Kalaycio M. Bendamustine: a new look at an old drug. Cancer115, 473–479 (2009).
   PubMed Web of Science ®Google Scholar
• Treon SP. How I treat Waldenstrom’s macroglobulinemia. Blood114(12), 2375–2385 (2009).
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Zomas A, Viniou NA et al. Treatment of Waldenstrom’s macroglobulinemia with thalidomide. J. Clin. Oncol.19, 3596–3601 (2001).
   PubMed Web of Science ®Google Scholar
• Hunter Z, Branagan A, Treon ST et al. Campath-1H in Waldenström’s macroglobulinemia. Blood104(11), (2004) (Abstract).
   PubMed Web of Science ®Google Scholar
• Treon S, Hunter Z, Matous J et al. Phase II study of bortezomib in Waldenstrom’s macroglobulinemia: results of WMCTG Trial 03-248. Blood106, (2005) (Abstract).
   PubMed Web of Science ®Google Scholar
• Chen CI, Kouroukis CT, White D et al. Bortezomib is active in patients with untreated or relapsed Waldenstrom’s macroglobulinemia: a Phase II study of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol.25(12), 1570–1575 (2007).
   PubMed Web of Science ®Google Scholar
• Treon SP, Ioakimidis L, Soumerai JD et al. Primary therapy of Waldenstrom macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG Clinical Trial 05-180. J. Clin. Oncol.27(23), 3830–3835 (2009).
   PubMed Web of Science ®Google Scholar
• Treon SP, Soumerai JD, Branagan AR et al. Thalidomide and rituximab in Waldenstrom macroglobulinemia. Blood112, 4452–4457 (2008).
   PubMed Web of Science ®Google Scholar
• Treon SP, Soumerai JD, Branagan AR et al. Lenalidomide and rituximab in Waldenstrom’s macroglobulinemia. Clin. Cancer Res.15, 355–360 (2009).
   PubMed Web of Science ®Google Scholar